The Messy, Complicated Nature of Assisted Reproductive Technology
By J. Wesley Judd,
Pacific Standard
| 09. 28. 2015
[cites CGS's Marcy Darnovsky]
Consensus is not a word used when talking about assisted reproductive technology, or ART, for short. In the past, we've reported on the controversial issues of designer babies and embryo adoption, but, recently, the Los Angeles Times detailed the particularly complex case of Dr. Mimi C. Lee and Stephen E. Findley, a divorced couple who are now battling over the future of their frozen embryo. It's a case that has the potential to set a legal precedent in California for disputes of this type.
"If Lee prevails, Findley could be forced to become a parent against his will. If Findley wins, it is extremely unlikely that Lee, now 46, will ever have a genetically related child," Times reporter Maura Dolan writes. Lee was diagnosed with cancer years ago, preventing her from being able to have a baby without the embryo.
While their particular case is newsworthy, ART is far from unique. According to the Centers for Disease Control and Prevention, in 2012, 65,000 babies were born via assisted reproductive technology—that’s 1.5 percent of all American infants.
But questions concerning the morality and legality of...
Related Articles
By Carly Mallenbaum, Axios [cites Emily Galpern] | 03.29.2026
More Americans are turning to surrogacy to build their families, as the practice becomes more common and more publicly discussed.
Why it matters: As surrogacy becomes more visible and accessible, ethical, legal and cultural tensions become harder to ignore...
By Carly Mallenbaum, Axios [cites Surrogacy360] | 03.29.2026
Without a federal law, surrogacy in the U.S. is governed by a patchwork of state regulations/
Why it matters: Confusing, varied local rules can determine everything from whether agreements are legally binding to who is recognized as a parent at...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
